Kymera Therapeutics Inc (KYMR) Stock Analysis

Kymera Therapeutics Inc (KYMR) is a publicly traded company in the HEALTHCARE sector. It trades at $71.29, carries a market capitalization of $6.45B. This page summarizes the public market data, fundamentals, and frequently asked questions for KYMR, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Kymera Therapeutics Inc currently has a Neutral sentiment score of 0.15.

About Kymera Therapeutics Inc

Kymera Therapeutics Inc. is a cutting-edge biopharmaceutical firm based in Watertown, Massachusetts, specializing in its proprietary protein degradation technology to transform treatment paradigms. By harnessing the body’s natural protein regulation mechanisms, Kymera develops targeted small molecule therapies aimed at selectively degrading harmful proteins associated with diseases such as cancer and autoimmune disorders. This innovative approach not only differentiates Kymera in the competit...

GNG Research Analysis

GNG Research scores Kymera Therapeutics Inc (KYMR) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for KYMR.

Frequently Asked Questions

Does KYMR pay dividends?

Kymera Therapeutics Inc (KYMR) does not currently pay a regular dividend.

What is KYMR's market cap?

Kymera Therapeutics Inc (KYMR) has a market capitalization of $6.45B with a current stock price of $71.29.